Patents Examined by Alicia L Otton
  • Patent number: 11414424
    Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: August 16, 2022
    Assignee: CYTOKINETICS, INC.
    Inventors: Chihyuan Chuang, Bradley P. Morgan, Mark Vanderwal, Luke W. Ashcraft, Kevin Lau
  • Patent number: 11414403
    Abstract: A new compound exhibiting particularly advantageous antibacterial properties, and having the structural formula: L-pyroglutamyl-L-1-aminoethyltetrazole (or N-(1-(1H-tetrazol-5-yl)ethyl)-5-oxopyrrolidine-2-carboxamide). Also, the use of this compound in microbiological culture methods and media intended for the detection, identification, enrichment, counting and/or isolation of target microorganisms that may be encountered in samples taken for clinical diagnosis or microbiological health control purposes.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: August 16, 2022
    Assignee: BIOMERIEUX
    Inventors: Rosaleen Anderson, Mark Gray, Laszlo Kondacs, Sylvain Orenga, John Perry
  • Patent number: 11407692
    Abstract: A method for oxidative cleavage of a compound with an unsaturated double bond is provided.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: August 9, 2022
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Chien-Tien Chen, Yi-Ya Liao, Ya-Pei Chen
  • Patent number: 11382912
    Abstract: An object of the present invention is to provide a controlled-release preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide as an active ingredient and having an excellent release property. Another object of the present invention is to provide a controlled-release preparation characterized by containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide, a water-soluble polymer, a functional starch, and an alkaline substance, and having a pH of 10 or more.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: July 12, 2022
    Assignee: NIPPON SHINYAKU CO., LTD.
    Inventors: Shouji Furuta, Naoto Hattori
  • Patent number: 11364240
    Abstract: Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: June 21, 2022
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Patent number: 11358956
    Abstract: There are provided compounds having formula (I), in which: X1 and X2 are selected from certain combinations of O, S, SO and SO2; X3 is selected from CH, CF and N; X4 is selected from CH and N; X6, X6? and X6? are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, and amide groups; X7 and X7? are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, aminoalkyl and amide groups, or both X7 and X7? together form a cycloalkyl or heterocycle; and A is selected from certain optionally substituted, alkoxy, piperazinyl and pyrrolidinyl groups. Also provided are compositions comprising these compounds, as well as uses/methods related thereto, including treatment of diseases and conditions associated with GPR119 dysregulation, Type 2 diabetes mellitus, and related metabolic disorders.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: June 14, 2022
    Assignee: PRAMANA PHARMACEUTICALS INC.
    Inventor: Mikhail Chafeev
  • Patent number: 11352326
    Abstract: Provided herein are compounds useful as imaging agents. Exemplary compounds provided herein are useful as myeloperoxidase imaging agents using positron emission tomography or fluorescence imaging techniques. Methods for preparing the compounds provided herein and diagnostic methods using radiolabeled and unlabeled compounds are also provided.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: June 7, 2022
    Assignee: The General Hospital Corporation
    Inventors: John W. Chen, Cuihua Wang, Edmund J. Keliher
  • Patent number: 11332484
    Abstract: Voltage sensitive dyes comprising boron and related compositions and methods are provided. In some embodiments, a voltage sensitive dye comprises an electron acceptor comprising boron. The electron acceptor may be attached (e.g., covalently) to at least one electron donating group and at least one polar group. For instance, the electron acceptor may comprise optionally substituted boron dipyrromethene (e.g., optionally substituted 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene). The point of attachment and chemical nature of the electron donating group(s) and polar group(s) may be selected to impart beneficial properties to the voltage sensitive dye. For instance, the voltage sensitive dye may have an extended difference in the dipole moment between the ground and electronic states due at least in part to the position of the electron donating group(s).
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: May 17, 2022
    Assignee: Akita Innovations LLC
    Inventors: Kevin M. Bardon, Richard A. Minns, Scott D. Selfridge, Larry Takiff, Timothy Adams
  • Patent number: 11319290
    Abstract: The invention relates to certain substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: May 3, 2022
    Assignee: Mebias Discovery, Inc.
    Inventors: Brett A. Tounge, Shariff Bayoumy, Lawrence C. Kuo, Scott L. Dax
  • Patent number: 11319328
    Abstract: Disclosed are a 4?-amino substituted podophyllotoxin derivative and a synthesis method therefor and the use thereof. The present invention respectively introduces the aromatic heterocyclic compounds anthraquinone, quinazoline, quinoline, indole, indazole, pyrimidine as substituent groups to position-4 of the C ring in the podophyllotoxin or 4?-demethylepipodophyllotoxin to obtain the podophyllotoxin derivatives as shown in formula (V). Experiments involving in vitro tumour cell activity inhibition show that the antitumour activity of most of the compounds as shown in formula (V) of the present invention is significantly improved compared to that of the patented medicine of podophyllotoxin-“etoposide”.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: May 3, 2022
    Inventor: Yajie Tang
  • Patent number: 11319291
    Abstract: Disclosed herein is a synthetic method, apparatus, and system for the continuous-flow synthesis of 3,4-dinitropyrazole from pyrazole in a microfluidic environment. This synthetic strategy consist of three (3) synthetic steps, including (1) N-nitration of pyrazole, (2) thermal rearrangement into 3-nitropyrazole, and (3) 4-nitration of 3-nitropyrazole. The current technique produces 3,4-dinitropyrazole in yields up to 85% in particular embodiments, in comparison to 40-50% yields demonstrated by the current state of-the-art batch process for large scale synthesis from pyrazole.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: May 3, 2022
    Assignee: United States of America as represented by the Secretary of the Air Force
    Inventors: Thorsten G. Schroer, Gregory E. Lecroy, Mayra P. Rodriguez, Sida Wang, Miguel Aguila
  • Patent number: 11306090
    Abstract: The present invention provides in one aspect azabicyclo and diazepine derivatives useful as modulators of muscarinic receptors. In another aspect, the present invention provides pharmaceutical compositions for treating ocular diseases, the compositions comprising at least one muscarinic receptor modulator.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: April 19, 2022
    Assignee: Alcon Inc.
    Inventors: David Ellis, Howard Allen Ketelson
  • Patent number: 11305016
    Abstract: The invention provides methods and pharmaceutical compositions for preventing or treating alopecia, such as chemotherapy-induced alopecia (CIA). The pharmaceutical compositions of the invention comprises an effective amount of a vitamin D compound in a formulation that topically delivers the vitamin D compound to the epidermis layer but substantially avoids the dermis layer. In chemotherapy patients, the pharmaceutical compositions of the invention can be administered either before or concurrent with the chemotherapy medication.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: April 19, 2022
    Assignee: Berg LLC
    Inventors: Joaquin J. Jimenez, Niven Rajin Narain, John Patrick McCook
  • Patent number: 11306097
    Abstract: The present invention relates to a method for synthesizing a compound of Formula (I) as defined herein, comprising: (i) activating a compound of Formula (II) as defined herein, by reacting said compound of Formula (II) with a compound of Formula (III) as defined herein, in the presence of a base, to obtain a compound of Formula (IV) as defined herein; and (ii) reacting the compound of Formula (IV) with an electrophile to obtain the compound of Formula (I). The present invention further relates to the organocatalysts used in the described methods and their respective uses.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: April 19, 2022
    Assignee: NANYANG TECHNOLOGICAL UNIVERSITY
    Inventors: Yonggui Chi, Zhenqian Fu
  • Patent number: 11278554
    Abstract: The present invention provides modified cycloalkyne compounds; and method of use of such compounds in modifying biomolecules. The present invention features a cycloaddition reaction that can be carried out under physiological conditions. In general, the invention involves reacting a modified cycloalkyne with an azide moiety on a target biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provide for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: March 22, 2022
    Assignee: The Regents of the University of California
    Inventors: Carolyn Ruth Bertozzi, Nicholas J. Agard, Jennifer A. Prescher, Jeremy Michael Baskin, Ellen May Sletten
  • Patent number: 11279684
    Abstract: The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: March 22, 2022
    Inventor: Christophe Henry
  • Patent number: 11274090
    Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: March 15, 2022
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Jonathan E. Wilson, Francois Brucelle, Julian R. Levell
  • Patent number: 11274076
    Abstract: A process for preparing a compound represented by Formula [1], the process comprising a step of hydrolyzing a compound represented by Formula [2] under an acidic or basic condition, and a step of reacting a compound represented by Formula [3] with a metal acetate salt, and a step of halogenating a compound represented by Formula [4]; a process for preparing a compound represented by Formula [1] comprising a step of reacting a compound represented by Formula [3] with a metal acetate salt, and then, adding alcohol, water, or base to the reaction solution to perform reaction; a process for preparing a compound represented by Formula [1] comprising a step of reacting a compound represented by Formula [3] under a presence or absence of a base, an ionic liquid and a metal sulfate salt, in water or a mixed solvent of water and an organic solvent; a compound represented by Formula [2] or a salt of the same; and a compound represented by Formula [3] or a salt of the same.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: March 15, 2022
    Assignee: GOWAN COMPANY, L.L.C.
    Inventors: Tsuyoshi Kawano, Makoto Bamba, Daisuke Horikoshi
  • Patent number: 11266642
    Abstract: A method for treating autoimmune thyroid disease is disclosed. The method comprises administering a molecule of molecular weight below 700 that inhibits the binding of the nonadecapeptide IPDNLFLKSDGRIKYTLNK (SEQ ID NO:1) to HLA-DR?1-Arg74.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: March 8, 2022
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Yaron Tomer, Roman Osman
  • Patent number: 11261201
    Abstract: Disclosed herein are secondary amine compounds that inhibit tRNA synthetase. The compounds of the invention are useful in inhibiting tRNA synthetase in Gram-negative bacteria and are useful in killing Gram-negative bacteria. The secondary amine compounds of the invention are also useful in the treatment of tuberculosis.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: March 1, 2022
    Assignee: President and Fellows of Harvard College
    Inventors: Daniel E. Kahne, Vadim Baidin